

PATIENT INFORMATION	Patient: _____ Caregiver: _____
	DOB: _____ <input type="checkbox"/> Male <input type="checkbox"/> Female Weight: _____ <input type="checkbox"/> kgs or <input type="checkbox"/> lbs (check one) Height _____ <input type="checkbox"/> in or <input type="checkbox"/> cm (check one) Recorded Date: _____
	Address: _____ City: _____ State: _____ Zip: _____
	Best Phone #: _____ <input type="checkbox"/> Cell Alternate Phone #: _____ <input type="checkbox"/> Cell Email: _____
	Allergies: _____ Latex Allergy: <input type="checkbox"/> Yes <input type="checkbox"/> No
ICD-10 Code for requested therapy: _____ ICD-10 Code(s) for other medical conditions: _____	

PLEASE FAX COPY OF ALL INSURANCE CARDS (FRONT & BACK) INCLUDING MEDICAL AND PRESCRIPTION

MEDICAL ASSESSMENT	TB/PPD Test Given? <input type="checkbox"/> Yes <input type="checkbox"/> No Date of negative TB test: _____ Hep B ruled out? <input type="checkbox"/> Yes <input type="checkbox"/> No	
	If no, treatment started? <input type="checkbox"/> Yes <input type="checkbox"/> No	
	Does patient have a latex allergy? <input type="checkbox"/> Yes <input type="checkbox"/> No _____% BSA affected by psoriasis Do the affected areas include the palms, soles, head, neck, or genitalia? <input type="checkbox"/> Yes <input type="checkbox"/> No Additional justification for drug: _____	PRIOR (FAILED) THERAPY: <input type="checkbox"/> Enbrel <input type="checkbox"/> Humira <input type="checkbox"/> Simponi <input type="checkbox"/> Stelara <input type="checkbox"/> Methotrexate <input type="checkbox"/> PUVA <input type="checkbox"/> UVB Topicals (please list): _____ Other (please list): _____

PLEASE PROVIDE ALL CLINICAL INFORMATION INCLUDING LAB RESULTS ON ALL FORMS

	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
PRESCRIPTION INFORMATION	Cimzia® (certolizumab)	<u>Starter Dose:</u> <input type="checkbox"/> Starter Kit (200mg Prefilled Syringes) <input type="checkbox"/> 200mg Lyophilized Vial	<input type="checkbox"/> 400mg Sub-Q at weeks 0, 2, and 4	<input type="checkbox"/> 1 Kit = 6 x 200mg/mL PFS <input type="checkbox"/> 3 Kits = 3 cartons of 2 x 200mg Vials	0
		Only for psoriatic arthritis <input type="checkbox"/> Enroll in Cimzia® Connect	<u>Maintenance Dose:</u> <input type="checkbox"/> 200mg/mL Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Vial	<input type="checkbox"/> 400mg Sub-Q every 4 weeks <input type="checkbox"/> 200mg Sub-Q every 2 weeks	<input type="checkbox"/> 1 Carton = 2 x 200mg/mL PFS <input type="checkbox"/> 1 Carton = 2 x 200mg Vials
	Cosentyx® (secukinumab)	<u>Starter Dose:</u> <input type="checkbox"/> 5 x 150mg/mL <input type="checkbox"/> 10 x 150mg/mL	<input type="checkbox"/> 150 mg SQ at week 0, 1, 2, 3 and 4 <input type="checkbox"/> 300 mg SQ at week 0, 1, 2, 3 and 4	_____ Pen OR _____ PFS	0
		<input type="checkbox"/> Enroll in Cosentyx® Connect	<u>Maintenance Dose:</u> <input type="checkbox"/> 1 x 150mg/mL <input type="checkbox"/> 2 x 150mg/mL	<input type="checkbox"/> 150 mg SQ every 4 weeks <input type="checkbox"/> 300 mg SQ every 4 weeks	_____ Pen OR _____ PFS
	Dupixent® (dupilumab)	<u>Starter Dose:</u> <input type="checkbox"/> 2 x 300mg/2 mL	<input type="checkbox"/> 600 mg SQ on day 1	1 x PFS	0
		<input type="checkbox"/> Enroll in Dupixent® MyWay	<u>Maintenance Dose:</u> <input type="checkbox"/> 1 x 300mg/2 mL	<input type="checkbox"/> 300 mg SQ every other week	_____ PFS
	Enbrel® (etanercept)	<u>Psoriasis Starter Dose:</u> <input type="checkbox"/> 8 x 50mg/mL x 3 months	<input type="checkbox"/> 50 mg SQ TWICE a week (72-96 hours apart) x 3 months	<input type="checkbox"/> 8 Sureclick Autoinjectors, OR <input type="checkbox"/> 8 PFS	2
				<input type="checkbox"/> 8 Mini Cartridge Solution for Injection	2
		<input type="checkbox"/> Enroll in Enbrel® Support <input type="checkbox"/> Enroll in Enbrel® Nurse Partner	<u>Maintenance Dose:</u> <input type="checkbox"/> 4 x 50mg/mL <input type="checkbox"/> 8 x 25mg/mL	<input type="checkbox"/> 50 mg SQ every week <input type="checkbox"/> 25 mg SQ TWICE a week	<input type="checkbox"/> 4 Sureclick Autoinjectors, OR <input type="checkbox"/> 4 PFS <input type="checkbox"/> 4 Mini Cartridge Solution for Injection <input type="checkbox"/> 8 x25mg PFS OR 8 x25mg Vials
	Humira® (adalimumab)	<u>Psoriasis Starter Dose:</u> <input type="checkbox"/> 4 x 40mg/0.8mL Pen	<input type="checkbox"/> 80 mg SQ day 1, then 40 mg every other week, starting 1 week after initial dose	<input type="checkbox"/> 4 Pens OR 4 PFS	0
<u>Hidradentitis Suppurativa Starter:</u> <input type="checkbox"/> 6 x 40mg/0.8mL		<input type="checkbox"/> 160 mg SQ day 1, then 80 mg on day 15, then 40 mg weekly starting on day 29	<input type="checkbox"/> 6 Pens OR 6 PFS	0	
<input type="checkbox"/> Enroll in Humira® Complete		<u>Maintenance Dose:</u> <input type="checkbox"/> 2 x 40mg/0.8mL <input type="checkbox"/> 4 x 40mg/0.8mL	<input type="checkbox"/> 40 mg SQ every two weeks <input type="checkbox"/> 40 mg SQ every week	<input type="checkbox"/> 2 Pens OR 2 PFS <input type="checkbox"/> 4 Pens OR 4 PFS	_____

MEDICATION		DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
PRESCRIPTION INFORMATION Otezla® (apremilast) <input type="checkbox"/> Enroll in Otezla® Support <input type="checkbox"/> Enroll in Otezla® Starter Kit Received	<u>Starter Dose:</u> <input type="checkbox"/> 28 days titrating dose Other _____	per manufacturer titrating dosing schedule _____	1 pack	0	
	<u>Maintenance Dose:</u> <input type="checkbox"/> 60 x 30mg tablets	<input type="checkbox"/> 30 mg po twice daily	_____ pack of 60 tabs)	_____	
Remicade® (infliximab) <input type="checkbox"/> Inflectra <input type="checkbox"/> Renflexis <input type="checkbox"/> Enroll in CarePath®	<u>Starter Dose:</u> <input type="checkbox"/> 5mg/kg	_____ mg IV infusion at weeks 0, 2, and 6	_____ Vial(s)	0	
	<u>Maintenance Dose:</u> <input type="checkbox"/> 100mg Lyophilized Vial(s)	_____ mg IV every 8 weeks	_____ Vial(s)	_____	
Simponi® (golimumab) Only for psoriatic arthritis <input type="checkbox"/> Enroll in CarePath®	<input type="checkbox"/> 1 x 50mg/0.5mL	<input type="checkbox"/> 50 mg SQ every month	_____ SmartJect Autoinjector	_____	
			OR _____ PFS		
Stelara™ (ustekinumab) <input type="checkbox"/> Enroll in CarePath®	<input type="checkbox"/> 45mg/0.5mL Prefilled Syringe <input type="checkbox"/> 90mg/1mL Prefilled Syringe	<u>Initiation Dose:</u> <input type="checkbox"/> Inject the contents of 1 prefilled syringe Sub-Q initially Day 1	<input type="checkbox"/> 1	0	
		<u>Maintenance Dose:</u> <input type="checkbox"/> Inject the contents of 1 prefilled syringe Sub-Q starting Day 29 & every 12 weeks thereafter	<input type="checkbox"/> 1	_____	
Taltz® (ixekizumab) <input type="checkbox"/> Enroll in Taltz® Savings Program	<u>Starter Dose:</u> <input type="checkbox"/> 2 x 80mg/mL <input type="checkbox"/> 6 x 80mg/mL	<input type="checkbox"/> 160 mg SQ at week 0 <input type="checkbox"/> 80 mg SQ at weeks 2, 4, 6, 8, 10, 12	<input type="checkbox"/> 2 PFS OR <input type="checkbox"/> 2 AutoInject <input type="checkbox"/> 6 PFS OR <input type="checkbox"/> 6 AutoInject	0 0	
	<u>Maintenance Dose:</u> <input type="checkbox"/> 1 x 80mg	<input type="checkbox"/> 80 mg SQ every 4 weeks	_____ PFS OR _____ Autoinject	_____	
Tremfya® (guselkumab) <input type="checkbox"/> Janssen CarePath®	<u>Starter Dose:</u> <input type="checkbox"/> 2 x 100mg/mL	<input type="checkbox"/> 100 mg SQ at weeks 0 and 4	2 PFS	_____	
	<u>Maintenance Dose:</u> <input type="checkbox"/> 1 x 100mg	<input type="checkbox"/> 100 mg SQ at week 8	_____ PFS	_____	
Other				_____	

INJECTION TRAINING: OFFICE TO COORDINATE USSC TO COORDINATE

PRESCRIBER INFORMATION	Anticipated Start Date: _____ Prescriber Specialty: _____
	Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Clinic <input type="checkbox"/> Other: _____
	Fax #: _____ Contact Name: _____
	Office Address: _____ City: _____ State: _____ Zip: _____
	The terms and conditions posted at www.usspecialtycare.com have been read by the person signing this form and are incorporated into this document by reference. The data privacy terms posted at www.usspecialtycare.com have been read by the person signing this form and are incorporated into this document by reference.
	<input type="checkbox"/> I understand that USSC may transfer this prescription to another pharmacy as an agent of the prescriber if unable to dispense.
Prescriber's Name: _____ Prescriber's Signature: _____ Date: _____	
<input type="checkbox"/> Use substitution <input type="checkbox"/> Dispense as Written	

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling (800)-641-8475 to obtain instructions as to the proper destruction of the transmitted material.